HTT and Huntington disease: Similarly, while a dose-dependent decrease in mutant HTT protein was observed in the CSF of patients with Huntington’s disease, there was no change in functional, neurological, psychiatric or cognitive outcomes in patients who received placebo versus those receiving active treatment [55].